M1 Kliniken AG publishes annual report for 2024

M1 Kliniken AG (ISIN: DE000A0STSQ8) today published its annual report for the 2024 financial year. The M1 Group continued on its growth trajectory, driven in particular by the high-margin Beauty segment. Looking ahead, the company sees substantial growth potential: revenues in the Beauty segment are expected to reach between EUR 200 and 300 million by 2029, with a targeted EBIT margin of at least 20%. The strategic goal is to establish M1 Med Beauty as the leading global brand for aesthetic treatments. M1 is already the market leader in Europe – offering the highest medical standards at the best price. With the proposed dividend of EUR 0.50 per share, the Management Board and Supervisory Board reaffirm the Group’s dividend policy.

Key Financial Highlights 2024

• Group revenue increased by 7% to EUR 339.2 million (previous year: EUR 316.3 million)
• EBITDA rose by 52% to EUR 32.0 million (previous year: EUR 21.0 million)
• EBIT grew by 70% to EUR 26.8 million (previous year: EUR 15.7 million)
• EBT increased by 60% to EUR 26.3 million (previous year: EUR 16.4 million)
• Beauty segment revenue rose by 30% to EUR 91.7 million (previous year: EUR 70.8 million)
• Equity ratio improved from 67% to 71%

Significant Increase in Profitability and Cash Flow

The consolidated net profit after minority interests rose markedly to EUR 16.0 million in 2024 (previous year: EUR 10.3 million). Earnings per share increased accordingly from EUR 0.54 to EUR 0.85. Operating cash flow more than tripled to EUR 30.5 million (previous year: EUR 7.8 million), while free cash flow improved significantly to EUR 24.9 million, compared to EUR -1.5 million in the previous year.